



INFUSION ORDERS

FAX: 470.922.3656 | **PHONE:** 470.377.6400

PATIENT INFORMATION:	Fax completed form, insurance information, and clinical documentation to 470.922.3656
Patient Name:	DOB: Phone:
	Continuing Therapy Next Treatment Date:
MEDICAL INFORMATION	
Patient Weight: lbs. (required)	Patient Height: inches
Allergies:	
	☐Granulomatosis w/ Polyangiitis ☐Microscopic Polyangiitis
_	Other:
ICD-10 :	
THERAPY ORDER	
	uximab biosimilar as required by patient's insurance
	to be determine after benefits investigation (noted below)
	use the following rituximab product:
	Omg Other:
Frequency: One time dose	onig — Other.
· · · _	wooks then repeat course every wooks OP
	weeks, then repeat course every weeks OR
months x	` '
_ * * *	weeks. One time order, do not repeat the course.
☐Weekly x 4 weeks	
□ Every 6 months x	
□ Other:	
Other orders	
Other orders:	
Protocol Premedication orders : Solu-	Medrol 100mg IV, Tylenol 1000mg PO, Benadryl 50mg PO/IV
☐ Other:	
Lab andone	Evanuaria.
Lab orders:	Frequency: h by: Infusion Center Referring Physician
	· · · · · · · · · · · · · · · · · · ·
*FOR BIOCARE INFUSION USE (DNLY
Brand:	
PROVIDER INFORMATION	
	care Infusion, and its employees to serve as your prior authorization and specialty pharmacy designated
agent in dealing with medical and prescription insurance companies, a	
Provider NPI: Phone:	Signature: Date: Fax: Contact Person:
□Opt out of Biocare Infusion selecting site	of care (if checked, please list site of care):
PREFERRED LOCATION	
City: State:	回答道 View our locations here: 漫画题
ony orace	view our locations here.



COMPREHENSIVE SUPPORT FOR

RITUXIMAB THERAPY

PATIENT INFORMATION:
Patient Name: DOB:
REQUIRED DOCUMENTATION FOR REFERRAL PROCESSING & INSURANCE APPROVAL
☐ Include <u>signed and completed</u> order (MD/prescriber to complete page 1)
☐ Include patient demographic information and insurance information
☐ Include patient's medication list
☐ Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits, or contraindications to conventional therapy
☐ Has the patient had a documented contraindication/intolerance or failed trial of a glucocorticoids? ☐ Yes ☐ No
☐ Does the patient have an intolerance or failed trial to a rituximab biosimilar? ☐ Yes ☐ No If yes, which drug(s)?
☐ If appliable: Has the patient had a documented contraindication/intolerance or failed trial of a DMARD, NSAID, or conventional therapy (i.e., MTX, leflunomide)? ☐ Yes ☐ No If yes, which drug(s)?
☐ If applicable: Does the patient have a contraindication/intolerance or failed trial to at least one biologic (i.e., Humira, Enbrel, Stelara, Cimzia)? ☐ Yes ☐ No If yes, which drug(s)?
☐ Supporting labs/diagnostics attached
If applicable - Last known biological therapy: and last date received: If patient is switching to biologic therapies, please perform a washout period of weeks prior to starting rituximab.
Other medical necessity:
REQUIRED PRE-SCREENING
☐ CBC w/platelet
 ☐ Hepatitis B screening test completed. This includes Hepatitis B surface antigen and Hepatitis B core antibody total (not IgM) - attach results ☐ Positive ☐ Negative
Recommended labs, but not required: Quantitative immunoglobulins *If Hepatitis B results are positive - please provide documentation of medical clearance* Biocare Infusion will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral. Please fax all information to (470) 922-3656 or call (470) 377-6400 for assistance